CMPX Compass Therapeutics Inc
Price (delayed)
$1.69
Market cap
$233.7M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.36
Enterprise value
$196.85M
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in
Highlights
CMPX's debt is down by 3.5% since the previous quarter
Compass Therapeutics's quick ratio has plunged by 53% from the previous quarter and by 27% YoY
The equity has contracted by 16% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of CMPX
Market
Valuations
Earnings
Shares outstanding
138.28M
Market cap
$233.7M
Enterprise value
$196.85M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.86
Price to sales (P/S)
273.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
231.59
Revenue
$850,000
Gross profit
$850,000
Operating income
-$56.63M
Net income
-$49.38M
EBIT
-$49.38M
EBITDA
-$47.62M
Free cash flow
-$44.9M
Per share
Balance sheet
Liquidity
EPS
-$0.36
EPS diluted
-$0.36
Free cash flow per share
-$0.33
Book value per share
$0.91
Revenue per share
$0.01
TBVPS
$1.02
Total assets
$140.4M
Total liabilities
$15.17M
Debt
$6.63M
Equity
$125.23M
Working capital
$123.88M
Debt to equity
0.05
Current ratio
14.96
Quick ratio
14.28
Net debt/EBITDA
0.77
Margins
Efficiency
Dividend
EBITDA margin
-5,602.6%
Gross margin
100%
Net margin
-5,808.8%
Operating margin
-6,661.8%
Return on assets
-32.6%
Return on equity
-34.8%
Return on invested capital
-41.8%
Return on capital employed
-37.5%
Return on sales
-5,808.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CMPX stock price
How has the Compass Therapeutics stock price performed over time
Intraday
-24.55%
1 week
-17.16%
1 month
-41.72%
1 year
-6.11%
YTD
16.55%
QTD
-11.05%
Financial performance
How have Compass Therapeutics's revenue and profit performed over time
Revenue
$850,000
Gross profit
$850,000
Operating income
-$56.63M
Net income
-$49.38M
Gross margin
100%
Net margin
-5,808.8%
The net income has declined by 16% year-on-year and by 3.4% since the previous quarter
The operating income has decreased by 12% YoY and by 2.1% from the previous quarter
CMPX's net margin is down by 3.4% since the previous quarter
The operating margin has declined by 2.1% since the previous quarter
Growth
What is Compass Therapeutics's growth rate over time
Valuation
What is Compass Therapeutics stock price valuation
P/E
N/A
P/B
1.86
P/S
273.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
231.59
The EPS has declined by 9% year-on-year
CMPX's price to book (P/B) is 64% higher than its last 4 quarters average of 1.5
The equity has contracted by 16% YoY and by 10% from the previous quarter
Efficiency
How efficient is Compass Therapeutics business performance
The ROIC has contracted by 39% YoY and by 10% from the previous quarter
The return on equity has declined by 33% year-on-year and by 7% since the previous quarter
Compass Therapeutics's return on assets has decreased by 33% YoY and by 6% QoQ
The return on sales has declined by 3.4% since the previous quarter
Dividends
What is CMPX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CMPX.
Financial health
How did Compass Therapeutics financials performed over time
The total liabilities has surged by 82% year-on-year and by 41% since the previous quarter
CMPX's current ratio has plunged by 53% from the previous quarter and by 24% YoY
CMPX's debt is 95% smaller than its equity
The equity has contracted by 16% YoY and by 10% from the previous quarter
CMPX's debt is down by 3.5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.